Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (14633)	2/11/1998 7:05:00 PM
From: Andrew H	Respond to of 32384

>>With the 72% number for Targretin and only 33% for Tamoxifen, can you determine if the Tamoxifen number is human or animal results. If the 33% number is animal and now is approved for humans, you would just have to think that Targretin will prove to be valid for humans(I HOPE, I HOPE).<< Dude, I am sure they are comparing targretin for rats with tamoxifen for rats as they did with their prior study a year ago. While rats are generally not a good cancer model for humans, they seemed to work well for diabetes. Actually I was surprised after the work 1 year ago that they didn't begin P2 for breast cancer right away. I suspect that these will translate into good human results, but we will have to wait and see--it is extrememly encouraging however.